Fig. 3. Combination of trametinib and fedratinib results in an anti-proliferative effect in MGC803, MIA PaCa-2, and PANC-1 cells through a decrease in the tyrosine phosphorylation levels of extracellular signal-regulated kinase (ERK) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) simultaneously. MGC803 (a), MIA PaCa-2 (b), and PANC-1 (c) cells were treated with a combination of trametinib (10 μmol/L) and fedratinib (2 μmol/L) for 24 h. (d) Cell lysates were collected for western blot analysis. The results are presented as mean±standard deviation (SD) from three independent experiments. ^* P<0.05 and ^*** P<0.001 vs. control; ^&& P<0.01 and ^&&& P<0.001 vs. 10 μmol/L trametinib treatment; ^## P<0.01 and ^### P<0.001 vs. 2 μmol/L fedratinib treatment.